v3.26.1
Segment Reporting
 12 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

12 Segment Reporting

 

Based on management’s assessment, the Company has determined that it has two operating segments as follows:

 

  1) Telemedicine and other services
  2) Sale of medicine and medical devices

 

             
   As of June 30, 
    2025    2024    2023 
    US$    US$    US$ 
                
Telemedicine and other services   6,800,287    12,857,688    6,898,166 
Sale of medicine and medical devices   846,452    1,110,847    976,720 
Total revenue   7,646,739    13,968,535    7,874,886 
                
Telemedicine and other services   5,630,553    10,487,767    5,948,232 
Sale of medicine and medical services   736,068    942,395    831,660 
Total cost of revenue   6,366,621    11,430,162    6,779,892 

 

The following tables present summary information by segment for the years ended June 30, 2025, 2024 and 2023, respectively:

 

          
   Years Ended June 30, 2025 
   Telemedicine and other services   Sale of medicine and medical devices   Consolidated totals 
   US$   US$   US$ 
             
Revenue   6,800,287    846,452    7,646,739 
Gross profit   1,169,734    110,384    1,280,118 
Loss before income tax expense   (3,132,486)   (251,320)   (3,383,806)
Net loss   (3,132,486)   (251,320)   (3,383,806)
                
Total reportable assets   4,104,014    343,936    4,447,950 

 

 

12 Segment Reporting (continued)

 

          
   Years Ended June 30, 2024 
   Telemedicine and other services   Sale of medicine and medical devices   Consolidated totals 
   US$   US$   US$ 
             
Revenue   12,857,688    1,110,847    13,968,535 
Gross profit   2,369,921    168,452    2,538,373 
Loss before income tax expense   (15,357,637)   (264,349)   (15,621,986)
Net loss   (15,338,443)   (264,349)   (15,602,792)
                
Total reportable assets   7,328,740    621,875    7,950,615 

 

          
   Years Ended June 30, 2023 
   Telemedicine services   Sale of medicine and medical devices   Consolidated totals 
   US$   US$   US$ 
             
Revenue   6,898,166    976,720    7,874,886 
Gross profit   949,934    145,060    1,094,994 
Loss before income tax expense   (2,965,165)   (248,195)   (3,213,360)
Net loss   (2,965,165)   (248,195)   (3,213,360)
                
Total reportable assets   3,121,643    320,896    3,442,539